- Conditions
- Chronic Hepatitis C
- Interventions
- valopicitabine, pegylated interferon, ribavirin
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Timeline
- Started 2005
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 448
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Hepatitis C
- Interventions
- Viramidine, Ribavirin, pegylated interferon alfa-2a
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 53
- States / cities
- Tucson, Arizona • Fresno, California • Los Angeles, California + 42 more
- Conditions
- Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
- Interventions
- ABT-450, ABT-072, ABT-333, Ritonavir, Peginterferon alpha-2a, Ribavirin, Placebo
- Drug · Other
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more
- Conditions
- Thrombocytopenia, Hepatitis C
- Interventions
- Eltrombopag
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hepatitis C, Chronic Pain
- Interventions
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 16
- States / cities
- La Jolla, California • San Diego, California • Ventura, California + 9 more
- Conditions
- Hepatitis C
- Interventions
- DCV/ASV/BMS-791325
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 42
- States / cities
- La Jolla, California • San Diego, California • San Francisco, California + 37 more
- Conditions
- Chronic Hepatitis C
- Interventions
- BMS-790052, Ortho Tri-Cyclen®
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Tempe, Arizona • Austin, Texas
- Conditions
- Hepatitis C Virus, HCV Infection, Chronic HCV, Hepatitis C
- Interventions
- Naringenin
- Dietary Supplement
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Hepatitis C Virus
- Interventions
- LDV/SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hepatitis C, Medication Adherence
- Interventions
- Patient Navigation, modified Directly Observed Therapy
- Behavioral
- Lead sponsor
- Prisma Health-Upstate
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 755 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- End Stage Renal Disease
- Interventions
- Zepatier, Mavyret
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hepatitis C
- Interventions
- Single Ascending Dose Cohorts GS-9620, Multiple Ascending Dose Cohorts GS-9620
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • DeLand, Florida • Orlando, Florida + 7 more
- Conditions
- Genotype 1 Chronic Hepatitis C, Treatment Naive
- Interventions
- Ribavirin, Telaprevir, Pegylated interferon alfa-2a
- Drug
- Lead sponsor
- Janssen Infectious Diseases BVBA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 37
- States / cities
- La Jolla, California • Los Angeles, California • San Diego, California + 34 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, PEGASYS, RO5024048 1500mg, RO5024048 3000mg
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 17
- States / cities
- La Jolla, California • Long Beach, California • Sacramento, California + 13 more
- Conditions
- Hepatitis C, Medication Adherence
- Interventions
- HepCure ToolKit, AdhereTech Active Features, AdhereTech Passive Monitoring
- Other · Device
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 21 Years to 89 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV Infections
- Interventions
- tipranavir, ritonavir
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Fort Lauderdale, Florida • Providence, Rhode Island + 2 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Pegasys, Placebo, RO5190591 (Danoprevir)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more
- Conditions
- Hepatitis C, Chronic, Hepatitis C, Opiate Dependence
- Interventions
- sofosbuvir/velpatasvir
- Drug
- Lead sponsor
- Community Research Initiative of New England
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Somerville, Massachusetts
- Conditions
- HIV Infections, Hepatitis C
- Interventions
- Ribavirin, Aldesleukin, Peginterferon alfa-2b
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Ribavirin (RBV), BI 201335 (Faldaprevir), BI 207127, Faldaprevir (BI 201335)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 24
- States / cities
- Dothan, Alabama • Chula Vista, California • La Mesa, California + 19 more
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo
- Drug · Other
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more
- Conditions
- HIV Infections, Hepatitis C, Liver Disease
- Interventions
- Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more
- Conditions
- Treatment of Hepatitis C
- Interventions
- Ledipasvir/Sofosbuvir FDC
- Drug
- Lead sponsor
- Peter J. Ruane, M.D., Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California